BioRestorative Therapies Operating Income

BioRestorative Therapies (BRTX) currently reports a operating income of $-14M as of March 2026. That compares with $-12M in the prior-year period — down 16.1% year over year. Use the charts on this page to explore BioRestorative Therapies's operating income history and peer comparisons.

BioRestorative Therapies's operating income decreased from $-12M to $-14M — a 16.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioRestorative Therapies reported $-14M in operating income as of March 2026. That compares with $-12M in the prior-year period — down 16.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioRestorative Therapies, and consider following BRTX for alerts when major investors trade the stock.

BioRestorative Therapies is classified in the Healthcare sector. On operating income, it currently shows $-14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BRTX with unrelated industries.